TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL-Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo

The aim of the present study was to prepare a tumor necrosis factor ligand superfamily member 10 (TRAIL) mutant membrane penetrating peptide alike (TMPPA), TRAIL-Mu3, and to investigate its antitumor effects in colorectal cancer in vitro and in vivo. The pMD19/TRAIL plasmid with designed primers was amplified to construct the target gene; it was ligated with an expression plasmid and the expression was confirmed. Subsequently, TRAIL-Mu3 was purified and further confirmed by western blot analysis. Immunofluorescence analysis was used to detect the distribution of TRAIL-Mu3 in colorectal cancer cells. In addition, the present study investigated the antitumor effects of TRAIL-Mu3 on colorectal cancer in vitro and in vivo. A novel TMPPA, TRAIL-Mu3, was synthesized in the present study. Following a series of detection experiments, it was confirmed that the TRAIL-Mu3 gene was obtained and was able to express TRAIL-Mu3 successfully. The immunofluorescence analysis demonstrated that TRAIL-Mu3 exhibited a markedly enhanced affinity to the colorectal cancer cell surface. In addition, TRAIL-Mu3 exerted stronger antitumor effects, compared with TRAIL, on colorectal cancer in vitro and in vivo.